Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Juliane Zielonka on September 22nd, 2022 | 11:58 CEST

Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation

  • Biotechnology
  • Covid19
  • Health

Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...

Read

Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST

BioNTech, XPhyto, Valneva - It is over!

  • Biotechnology
  • Covid19
  • Cannabis

In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.

Read

Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST

Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?

  • Biotechnology
  • Cancer
  • vaccine

Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.

Read

Commented by Stefan Feulner on September 13th, 2022 | 11:34 CEST

BioNTech, Cardiol Therapeutics, Bayer - Caution, turnaround!

  • Biotechnology
  • Turnaround

The market correction due to geopolitical uncertainties and fears of further interest rate hikes mainly affected growth stocks in recent months, with the capital-intensive biotech sector losing disproportionately. However, the industry is growing dynamically and will become increasingly important in the coming years in the fields of application of the pharmaceutical and chemical industry, in the agricultural and food sector and in environmental protection. Due to the market correction, there are currently enormous opportunities for a turnaround in selected stocks.

Read

Commented by Fabian Lorenz on September 9th, 2022 | 10:53 CEST

300% chance with MorphoSys share? News from BioNTech and Defence Therapeutics

  • Biotechnology

Analysts see a 300% price potential for MorphoSys. However, the latest quarterly figures did not give cause for euphoria. And not all analysts are so positive. On the other hand, BioNTech is currently doing well. The Mainz-based Company has received approval for its Omicron vaccine in the UK. However, the sustainable share price is increasingly determined by the pipeline. There is important news concerning the pipeline at Defence Therapeutics. In preclinical studies for the development of a novel cellular vaccine to fight cancer, the survival rate was 100%. The Canadians' unconventional approach could revolutionize modern medicine. More on the three biotech stocks here.

Read

Commented by Nico Popp on September 7th, 2022 | 12:18 CEST

Minimum risk, maximum opportunity: Thyssenkrupp, Saturn Oil + Gas, BioNTech

  • Mining
  • Oil
  • Biotechnology
  • Steel

The energy price hammer, possible gas rationing in winter, and then there was the pandemic - but which issues end up impacting share prices? Are the risks around energy shortages already adequately priced into the industry? Are energy companies even fairly valued? And what opportunities can BioNTech still offer? We look at three stocks and provide an overview of opportunities and risks.

Read

Commented by Armin Schulz on September 5th, 2022 | 11:49 CEST

BioNTech, Cardiol Therapeutics, Formycon - Biotech stocks about to make a comeback?

  • Biotechnology
  • Turnaround

Fears of a recession have recently pushed the markets down again. Those who want to bet on crisis-proof investments should look at biotech stocks. The world population is growing, people are getting older, and in line with age, more diseases are appearing. This trend will continue in the coming years. Therefore, the prospects for success in this sector are excellent. One cannot cut corners on health. Since September 2021, shares of biotech companies have also consolidated strongly. In some cases, shares appear severely undervalued. Today, we look at three interesting companies in the biotech sector.

Read

Commented by Nico Popp on September 1st, 2022 | 14:05 CEST

New trending stock in the wings? Plug Power, Cardiol Therapeutics, BioNTech

  • Biotechnology
  • Cannabis
  • Hydrogen

The markets want to go up! Last Friday, the Fed shock worried the markets, but today, even speculative stocks are picking up again. Especially stocks that were long considered deregistered can quickly develop potential. One example is Plug Power. Here, new demand in the wake of high energy prices meets good products. We explain the secret to the success of comeback stocks, using Plug Power as an example, and highlight new opportunities.

Read

Commented by Fabian Lorenz on August 31st, 2022 | 11:46 CEST

Poison pill slows down Nel share - will BioNTech and Almonty Industries soon take off?

  • Mining
  • Tungsten
  • Hydrogen
  • Biotechnology

The Nel ASA share is currently not for the faint-hearted. The stock is caught between hydrogen euphoria and a downward chart trend. Yet the news from the Company and the industry - such as the deal between Plug Power and Amazon - has been positive overall recently. But there is a poison pill. In contrast, the coming week could be exciting for BioNTech shareholders. In Germany, deliveries of the Corona vaccine, which has been adapted to virus variants, is scheduled to start. This could also give the shares of the German biotech flagship a new lease of life. The Almonty share could also soon break the knot. The discussion about reducing dependence on China for raw materials is picking up speed. Consistent with this, Almonty reports progress in the development of the tungsten mine in South Korea.

Read

Commented by André Will-Laudien on August 30th, 2022 | 12:35 CEST

Do not miss the turnaround: BioNTech, MorphoSys, Tocvan Ventures, TUI - shares on the move!

  • Mining
  • Gold
  • Biotechnology
  • travel

Making money on the stock market these days is not easy. Volatility is very high as the economy adjusts to entirely new conditions. Consumers have heavy loads to carry due to the energy crisis, and the still available household budgets are melting like ice in the sun in the face of inflation everywhere. Once again, fears are spreading that there might not be enough for a quiet retirement, and the savings rate is rising sharply. Those who remain active on the markets should proceed consistently according to analytical criteria because the dream of the eternal bull market is over for the time being. Here is a selection of good opportunities.

Read